BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31848710)

  • 1. The relationship between plasma GIP and GLP-1 levels in individuals with normal and impaired glucose tolerance.
    Marathe CS; Pham H; Marathe JA; Trahair LG; Huynh L; Wu T; Phillips LK; Rayner CK; Nauck MA; Horowitz M; Jones KL
    Acta Diabetol; 2020 May; 57(5):583-587. PubMed ID: 31848710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of incretin on early-phase insulin secretion and glucose excursion.
    Shen J; Chen Z; Chen C; Zhu X; Han Y
    Endocrine; 2013 Oct; 44(2):403-10. PubMed ID: 23283820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Older Subjects With β-Cell Dysfunction Have an Accentuated Incretin Release.
    de Jesús Garduno-Garcia J; Gastaldelli A; DeFronzo RA; Lertwattanarak R; Holst JJ; Musi N
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2613-2619. PubMed ID: 29672742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.
    Rask E; Olsson T; Söderberg S; Holst Jj Jj; Tura A; Pacini G; Ahrén B
    Metabolism; 2004 May; 53(5):624-31. PubMed ID: 15131768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
    Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus.
    Cypryk K; Vilsbøll T; Nadel I; Smyczyńska J; Holst JJ; Lewiński A
    Gynecol Endocrinol; 2007 Jan; 23(1):58-62. PubMed ID: 17484514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Changes in Fasting and Glucose-Stimulated GLP-1 and GIP in Healthy Older Subjects.
    Pham H; Marathe CS; Phillips LK; Trahair LG; Hatzinikolas S; Huynh L; Wu T; Nauck MA; Rayner CK; Horowitz M; Jones KL
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6201-6206. PubMed ID: 31393567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance.
    Ahrén B; Larsson H; Holst JJ
    Eur J Endocrinol; 1997 Aug; 137(2):127-31. PubMed ID: 9272099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.
    Greenfield JR; Farooqi IS; Keogh JM; Henning E; Habib AM; Blackwood A; Reimann F; Holst JJ; Gribble FM
    Am J Clin Nutr; 2009 Jan; 89(1):106-113. PubMed ID: 19056578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal Responses to Cholinergic Input Are Different in Humans with and without Type 2 Diabetes Mellitus.
    Chowdhury S; Wang S; Dunai J; Kilpatrick R; Oestricker LZ; Wallendorf MJ; Patterson BW; Reeds DN; Wice BM
    PLoS One; 2016; 11(6):e0156852. PubMed ID: 27304975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O; Haugaard SB; Holst JJ; Deacon CF; Iversen J; Andersen UB; Nielsen JO; Madsbad S
    HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Yokoyama H; Haneda M
    Front Endocrinol (Lausanne); 2020; 11():214. PubMed ID: 32390941
    [No Abstract]   [Full Text] [Related]  

  • 14. Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits.
    Gjesing AP; Ekstrøm CT; Eiberg H; Urhammer SA; Holst JJ; Pedersen O; Hansen T
    Diabetologia; 2012 May; 55(5):1338-45. PubMed ID: 22349073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic.
    Tura A; Muscelli E; Gastaldelli A; Ferrannini E; Mari A
    Diabetologia; 2014 Jun; 57(6):1199-203. PubMed ID: 24658843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
    Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1363-70. PubMed ID: 22319034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
    Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 and GIP Levels in Patients With Hyperthyroidism: The Effect of Antithyroid Treatment.
    Cira DK; Sari R; Ozdem S; Yilmaz N; Bozkurt S
    Ann Pharmacother; 2017 Aug; 51(8):663-668. PubMed ID: 28452237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.